Table 2.
Cell growth inhibition in HL60 and its multidrug resistant variant HL60R following treatment with essential oil of A. procera and doxorubicin (Doxo) or a combination of these.
| Cell Lines and Treatments | Cell Viability (%) | Expected (%) |
|---|---|---|
| HL60 | ||
| Essential oil of A. procera 10 μg/mL | 100.0 ± 0.0 | |
| Essential oil of A. procera 20 μg/mL | 82.0 ± 2.1 | |
| Doxo 1 ng/mL | 90.0 ± 0.7 | |
| Doxo 2 ng/mL | 84.5 ± 3.9 | |
| Essential oil of A. procera 10 μg/mL + Doxo 1ng/mL | 100.0 ± 0.5 | 90.0 ± 0.7 |
| Essential oil of A. procera 10 μg/mL + Doxo 2 ng/mL | 93.0 ± 3.1 | 84.5 ± 3.9 |
| Essential oil of A. procera 20 μg/mL + Doxo 1 ng/mL | 80.0 ± 1.7 | 74.0 ± 1.4 |
| Essential oil of A. procera 20 μg/mL + Doxo 2 ng/mL | 71.0 ± 2.2 | 69.0 ± 1.4 |
| HL60R | ||
| Essential oil of A. procera 10 μg/mL | 100.0 ± 0.0 | |
| Essential oil of A. procera 20 μg/mL | 70.5 ± 3.2 | |
| Doxo 100 ng/mL | 87.5 ± 3.9 | |
| Doxo 500 ng/mL | 76.5 ± 4.6 | |
| Essential oil of A. procera 10 μg/mL + Doxo 100 ng/mL | 95.0 ± 2.2 | 87.5 ± 3.9 |
| Essential oil of A. procera 10 μg/mL + Doxo 500 ng/mL | 88.0 ± 3.8 | 76.5 ± 4.6 |
| Essential oil of A. procera 20 μg/mL + Doxo 100 ng/mL | 70.0 ± 1.9 | 62.0 ± 5.6 |
| Essential oil of A. procera 20 μg/mL + Doxo 500 ng/mL | 61.0 ± 5.9 | 54.0 ± 5.6 |
Data are expressed as the mean ± standard error of three independent experiments. There are not statistical differences among expected (%) and cell viability (%). Expected value: Sum of the effects of the agents alone minus that of the untreated cells.